Stress Echo 2020 - The International Stress Echo Study

NCT03049995 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2021-10-11

No results posted yet for this study

Summary

Background: Stress echocardiography (SE) has an established role in evidence-based guidelines, but recently the breadth and variety of applications has extended well beyond coronary artery disease (CAD). Purpose: To establish a prospective research study of SE applications, in and beyond CAD, also considering a variety of signs in addition to regional wall motion abnormalities. Methods: In a prospective, multicenter, international, observational study design, \> 100 certified high-volume SE labs will be networked with an organized system of clinical, laboratory and imaging data collection at the time of physical or pharmacological SE, with structured follow-up information. The study is endorsed by the Italian Society of Echocardiography and organized in 10 subprojects focusing on: contractile reserve for prediction of cardiac resynchronization or medical therapy response; stress B-lines in heart failure; hypertrophic cardiomyopathy; heart failure with preserved ejection fraction; mitral regurgitation after either transcatheter or surgical aortic valve replacement; outdoor SE in extreme physiology; right ventricular contractile reserve in repaired tetralogy of Fallot; suspected or initial pulmonary arterial hypertension; coronary flow velocity, left ventricular elastance reserve and B-lines in known or suspected CAD; identification of subclinical familial disease in phenotype-negative healthy relatives of inherited disease (such as hypertrophic cardiomyopathy). Expected Results:To collect about 10,000 patients over a 5-year period (2016-2020), with sample sizes ranging from 5,000 for known or suspected CAD to around 250 for hypertrophic cardiomyopathy or repaired Fallot. This data base will allow to investigate technical questions such as feasibility and reproducibility of various SE parameters and to assess their prognostic value in different clinical scenarios. Conclusions: The study will create the cultural, informatic and scientific infrastructure connecting high-volume, accredited SE labs, to obtain original safety, feasibility, and outcome data in evidence-poor diagnostic fields, also outside the established core application of SE in CAD based on regional wall motion abnormalities. The study will standardize procedures, validate emerging signs, and integrate the new information with established knowledge, helping to build a next-generation SE lab without inner walls.

Conditions

Interventions

PROCEDURE

Left ventricular contractile reserve SE

Stress protocols (either physical or pharmacological) will be performed according to recent guidelines recommendations (1,2,3). with special focus on Wall Motion Score Index.

PROCEDURE

B-lines SE

SE will be performed with special focus on lung sonography and B-lines score (3,4).B-lines will be scored with the 28-regions antero-lateral chest assessment as previously described at baseline and immediately after stopping exercise. A simplified 8-region scan is also allowed in order to save time without loss of critical information.

PROCEDURE

Left ventricular outflow tract gradient SE

SE will be performed with special focus on left ventricular outflow tract obstruction (3,4).

PROCEDURE

Diastolic function SE

SE will be performed with special focus on E/e', pulmonary artery systolic pressure, B-lines and left ventricular end-diastolic volume (3,4).

PROCEDURE

Mitral regurgitation SE

SE will be performed with special focus on mitral regurgitation and aortic valve gradients assessment (3,4).

PROCEDURE

Pulmonary hemodynamics SE

SE will be performed with special focus on pulmonary artery systolic pressure and pulmonary artery hemodynamics.

PROCEDURE

Coronary flow reserve SE

SE will be performed with special focus on regional wall motion + coronary artery flow velocity reserve.

Sponsors & Collaborators

  • Institute of Clinical Physiology, CNR, Pisa,Italy

    collaborator UNKNOWN
  • Salerno Hospital, Italy

    collaborator UNKNOWN
  • Monaldi Hospital, Napoli, Italy

    collaborator UNKNOWN
  • University of Pisa

    collaborator OTHER
  • San Luca Hospital, Lucca, Italy

    collaborator UNKNOWN
  • Careggi Hospital

    collaborator OTHER
  • Federico II University

    collaborator OTHER
  • San Carlo Public Hospital, Potenza, Italy

    collaborator OTHER
  • Royal Brompton & Harefield NHS Foundation Trust

    collaborator OTHER
  • Ospedale dell'Angelo, Venezia-Mestre

    collaborator OTHER
  • University of Parma

    collaborator OTHER
  • Hospital Clinics, Trieste, Italy

    collaborator UNKNOWN
  • Federal University of Rio Grande do Sul

    collaborator OTHER
  • Hospital San José, Criciuma, Brasil

    collaborator UNKNOWN
  • Hospital San Vicente de Paulo, Passo Fundo, Brasil

    collaborator UNKNOWN
  • University of Belgrade

    collaborator OTHER
  • University of Szeged, Hungary

    collaborator UNKNOWN
  • Elisabeth Hospital, Hodmezovasarhely, Hungary

    collaborator UNKNOWN
  • Sandro Pertini Hospital, Rome, Italy

    collaborator UNKNOWN
  • Hospital Clinics, Bari, Italy

    collaborator UNKNOWN
  • Ospedale Nottola, Siena, Italy

    collaborator UNKNOWN
  • University of Catania, Italy

    collaborator UNKNOWN
  • Medika Cardiocenter, Saint Petersburg, Russian Federation

    collaborator UNKNOWN
  • Acibadem City Clinic Tokuda Hospital

    collaborator OTHER
  • Investigaciones Medicas, Buenos Aires, Argentina

    collaborator UNKNOWN
  • Tomsk National Research Scientific Centre of Russian Academy of Sciences, Tomsk, Russian Federation

    collaborator UNKNOWN
  • Instituto Nacional de Cardiología Mexico City, Mexico

    collaborator UNKNOWN
  • Hamad Medical Corporation, Heart Hospital -Doha-Qatar

    collaborator UNKNOWN
  • Fatebenefratelli Hospital

    lead OTHER

Principal Investigators

  • Quirino Ciampi, MD · Fatebenefratelli Hospital

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2020-12-31
Completion
2021-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03049995 on ClinicalTrials.gov